I have been posting for quite some time that absent an imminent cash partnership that there would be a palatable financing solution until such a partnership can be completed (my guess is the latest before Q-2) Remember, breakeven cash is projected for 2018. TIME FOR BIG-LOSS, OLD-TIMERS TO AVERAGE DOWN IMO! (I already have done so big-time before the latest news).
I think Lincoln Park Capital acts more like the chief financial backer for CYTX and Martell is their man sitting on the board of directors. Lincoln Park must have done in depth DD and B Riley is a part of the efforts.
CYTX is going solo at least for the near future, just like VCEL and many other stem cells companies.
$20 in 2017 a tall order imho
Since the on going increase in shares will be happening, I think market cap a better projection tool. So, with a successful p3 scleroderma result, a $200 million market cap would seem appropriate with the on going debt a mitigating factor. FDA approval $400 million, perhaps much more, depending on whats going on with the company and the perception of the street.
Hedgefund, I agree that $20 in 2017 is a reach and requires that everything must fall in place on a timely basis - certainly, there can be no missteps as CYTX has tended to have in the past - I am very confident although I can understand why most old-timers will continue to be skeptical.